PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10570446-0	1999	Octreotide improves biochemical, radiologic, and symptomatic indices of gastroenteropancreatic neoplasia in patients with multiple endocrine neoplasia type 1 (MEN-1).	Octreotide	0-10	menin 1	Homo sapiens	122-157	
10570446-0	1999	Octreotide improves biochemical, radiologic, and symptomatic indices of gastroenteropancreatic neoplasia in patients with multiple endocrine neoplasia type 1 (MEN-1).	Octreotide	0-10	menin 1	Homo sapiens	159-164	
10570446-5	1999	The authors attempted to determine the role of the somatostatin analogue, octreotide, in ameliorating features of hypergastrinemic GEP neoplasia associated with MEN-1.	Octreotide	74-84	menin 1	Homo sapiens	161-166	
31818296-0	2019	Case report: optimal tumor cytoreduction and octreotide with durable disease control in a patient with MEN-1 and Zollinger-Ellison syndrome-over a decade of follow-up.	Octreotide	45-55	menin 1	Homo sapiens	103-108	
31818296-4	2019	This case report supports consideration for aggressive tumor cytoreduction and octreotide in similar patients with MEN-1-associated ZES for durable disease control and symptom management.	Octreotide	79-89	menin 1	Homo sapiens	115-120	
31183223-5	2019	A 43-year-old male with a history of MEN1 and multiple subcentimeter neuroendocrine tumors with elevation of PP was treated with octreotide therapy leading to a reduction and normalization of PP levels.	Octreotide	129-139	menin 1	Homo sapiens	37-41	
31183223-8	2019	In patients with MEN1 and subcentimeter pNETs, octreotide therapy is well tolerated and can lead to a significant drop in PP levels with no change in lesion size.	Octreotide	47-57	menin 1	Homo sapiens	17-21	
28458907-15	2017	PRL-ACTH-producing tumor is a very rare type of pituitary tumor, and treatment with cabergoline and octreotide may be useful for controlling hormone levels secreted from a plurihormonal pituitary adenoma, as seen in this case of MEN1.	Octreotide	100-110	menin 1	Homo sapiens	229-233	
29263719-0	2017	The LARO-MEN1 study: a longitudinal clinical experience with octreotide Long-Acting Release in patients with Multiple Endocrine Neoplasia type 1 Syndrome.	Octreotide	61-71	menin 1	Homo sapiens	4-13	
18485119-0	2008	Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.	Octreotide	53-63	menin 1	Homo sapiens	104-139	
22970022-10	2012	In the GES-1 and MKN-28 cells undergoing octreotide treatment, cytoplasmic menin was significantly increased compared with the control groups.	Octreotide	41-51	menin 1	Homo sapiens	75-80	
24443791-0	2014	Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours.	Octreotide	22-32	menin 1	Homo sapiens	62-66	
24443791-3	2014	AIM: To evaluate the efficacy of the long-acting SSA octreotide in MEN1 patients with early-stage duodeno-pancreatic NETs.	Octreotide	53-63	menin 1	Homo sapiens	67-71	
18485119-0	2008	Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.	Octreotide	53-63	menin 1	Homo sapiens	141-145	
18485119-2	2008	OBJECTIVE: To evaluate the effects of depot long acting octreotide (OCT-LAR) in patients with MEN1-related PHP.	Octreotide	56-66	menin 1	Homo sapiens	94-98